optic neuritis: Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain.The conditionmay cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis , drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.
Retrobulbar neuritis in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
H7_RETROBULBNEURINOTH
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
138 |
4. Check minimum number of eventsNone |
138 |
5. Include endpointsNone |
138 |
6. Filter based on genotype QC (FinnGen only) |
129 |
Control definitions (FinnGen only)
- Control exclude
- H7_OPTNERVE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Retrobulbar neuritis in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Disorders of optic nerve and visual pathways
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 604 | 436 | 164 |
| Only index persons | 579 | 422 | 157 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 41.59 | 42.05 | 40.49 |
| Only index persons | 41.30 | 41.71 | 40.20 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 129 | 102 | 27 |
| Unadjusted period prevalence (%) | 0.03 | 0.04 | 0.01 |
| Median age at first event (years) | 40.14 | 39.68 | 41.88 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 138
- Matched controls
- 1380
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G35
ICD-10 Finland
Multiple sclerosis
1568.7
150.8
121
6
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
139.1
109
*
109
Kela drug reimbursment
Multiple sclerosis
963.7
129.4
108
5
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
761.5
119.7
102
5
H46
ICD-10 Finland
Optic neuritis
+∞
102.2
85
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
506.6
101.7
90
5
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
21.3
74.3
74
71
XCK00
NOMESCO Finland
Perimetry
32.8
72.5
52
25
L03AB07
ATC
interferon beta-1a; parenteral
555.2
67.9
62
*
N86
ICPC
Multiple sclerosis
+∞
59.8
53
*
L03AX13
ATC
glatiramer acetate; parenteral
341.1
48.3
46
*
TAB00
NOMESCO Finland
Lumbar puncture
16.1
46.8
47
43
164
Kela drug reimbursment
Fingolimod
609.3
46.1
43
*
353
Kela drug reimbursment
Cladribine and fingolimod
549.2
42.6
40
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
14.3
39.8
42
41
L04AA27
ATC
[U] fingolimod
+∞
39.5
36
*
ZX120
NOMESCO Finland
Intravenous
12.2
39.4
48
58
L03AB08
ATC
interferon beta-1b; parenteral
415.4
33.4
32
*
XKD00
NOMESCO Finland
Uroflowmetry
12.6
33.1
37
39
L04AX07
ATC
dimethyl fumarate; oral
143.2
32.3
33
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
44.6
32.1
39
12
N04BB01
ATC
amantadine; oral
107.3
31.3
33
*
2AB04, ,
NOMESCO Finland
198.0
31.1
31
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
12.3
28.8
32
33
XA800
NOMESCO Finland
Neuropsychological investigation
11.3
27.1
32
36
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
90.8
27.0
29
*
H02AB04
ATC
methylprednisolone; systemic
6.9
25.1
51
108
Z01.0
ICD-10 Finland
Examination of eyes and vision
6.6
25.0
55
126
L04AA31
ATC
[U] teriflunomide
+∞
23.6
22
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
55.4
23.3
27
6
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
22.5
21
*
XKD06
NOMESCO Finland
Physiologic investigation of micturition
31.5
21.5
28
11
XCW99
NOMESCO Finland
Other investigative procedure of eye
7.5
21.4
36
62
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
20.3
19
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
24.7
20.1
28
14
M03BX01
ATC
baclofen; systemic
28.7
19.5
26
11
XCD10
NOMESCO Finland
Electrophysiological examination of eye
26.3
19.0
26
12
G04BD12
ATC
mirabegron; oral
7.7
18.9
30
48
Z3231
NOMESCO Finland
Registered nurse
4.6
17.7
65
222
Z3226
NOMESCO Finland
Physiotherapist
4.8
16.5
50
146
N07XX09
ATC
[U] dimethyl fumarate
68.4
16.2
18
*
4AA23, ,
NOMESCO Finland
+∞
15.9
15
*
G04BD04
ATC
oxybutynin; oral, transdermal
8.2
15.8
23
33
H48.1*A69.2
ICD-10 Finland
Retrobulbar neuritis in Lyme disease
+∞
14.8
14
*
Z3229
NOMESCO Finland
Other healthcare associate professional
6.6
14.5
26
47
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
27.3
14.2
19
8
G04BD09
ATC
trospium; oral
32.0
13.3
17
6
R4110
NOMESCO Finland
Physiotherapy
3.7
12.8
61
241
XF400
NOMESCO Finland
ECG with 12 standard connections
4.9
12.8
33
83
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.0
12.8
25
49
L04AE01
ATC
fingolimod; oral
+∞
12.7
12
*
UKC02
NOMESCO Finland
Cystoscopy
5.2
12.1
28
64
N05CF01
ATC
zopiclone; oral
3.5
11.7
59
240
H47.2
ICD-10 Finland
Optic atrophy
+∞
11.6
11
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
22.4
11.4
16
8
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
47.5
11.1
13
*
Z2446
NOMESCO Finland
Social worker
6.0
11.0
21
40
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
30.9
11.0
14
5
N03AE01
ATC
clonazepam; systemic
9.0
10.9
23
30
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
10.9
44
154
TKC20
NOMESCO Finland
Catheterisation of bladder
9.5
10.8
22
27
N39.4
ICD-10 Finland
Other specified urinary incontinence
5.4
10.7
23
49
R1250
NOMESCO Finland
Evaluation of functional capability
17.9
10.6
16
10
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
10.5
10
*
ZXD10
NOMESCO Finland
Scheduled procedure
3.2
10.0
68
325
L04AX01
ATC
azathioprine; systemic
9.5
10.0
20
24
Z2221
NOMESCO Finland
Medical doctor
3.2
9.9
62
282
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.3
9.6
28
77
N06BA07
ATC
modafinil; oral
32.6
9.6
12
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
+∞
9.5
9
*
L04AG12
ATC
ofatumumab; parenteral
+∞
9.5
9
*
J01EA01
ATC
trimethoprim; systemic
3.2
9.5
55
239
A28
ICPC
Limited function/disability NOS
4.5
9.2
25
65
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
5.5
9.1
19
39
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.1
9.1
28
80
ZXA10
NOMESCO Finland
Bilateral
3.6
9.1
36
123
R4120
NOMESCO Finland
Occupational therapy
5.0
9.0
21
48
Z2445
NOMESCO Finland
Psychologist
7.3
8.9
21
33
R35
ICD-10 Finland
Polyuria
7.3
8.9
21
33
N99
ICPC
Neurological disease other
53.5
8.8
10
*
R2110
NOMESCO Finland
Giving the first information
4.9
8.8
21
49
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.0
8.7
20
45
H53.1
ICD-10 Finland
Subjective visual disturbances
4.6
8.4
22
55
A02BC02
ATC
pantoprazole; systemic
3.3
8.4
105
682
R4150
NOMESCO Finland
Neuropsychological rehabilitation
18.6
8.2
12
7
G04BD08
ATC
solifenacin; oral
7.8
8.1
18
26
R42
ICD-10 Finland
Dizziness and giddiness
3.2
8.0
38
145
N30.0
ICD-10 Finland
Acute cystitis
3.3
7.9
36
134
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
26.7
7.7
10
*
N28
ICPC
Limited function/disability (N)
26.7
7.7
10
*
L04AA40
ATC
cladribine; oral
84.4
7.5
8
*
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
11.8
7.5
13
12
R20.2
ICD-10 Finland
Paraesthesia of skin
3.9
7.4
24
71
N29
ICPC
Neurological sympt/complt other
16.9
7.4
11
7
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
+∞
7.4
7
*
L04AK02
ATC
teriflunomide; oral
+∞
7.4
7
*
N03AX12
ATC
[U] gabapentin; oral
3.1
7.3
36
140
H53.9
ICD-10 Finland
Visual disturbance, unspecified
7.7
7.2
16
23
N03AX16
ATC
[U] pregabalin
2.9
7.1
42
180
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
7.4
7.1
16
24
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
14.8
7.0
11
8
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.4
7.0
29
101
ZXE10
NOMESCO Finland
More than one and less than three hours
2.6
6.9
60
314
L28
ICPC
Limited function/disability (L)
3.4
6.8
27
91
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
42.2
6.8
8
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
42.2
6.8
8
*
U07
ICPC
Urine symptom/complaint other
4.6
6.8
17
41
R5110, ,
SPAT
7.5
6.7
15
22
H02AB07
ATC
prednisone; oral
3.4
6.7
27
92
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
15.3
6.5
10
7
G04BD07
ATC
tolterodine; oral
8.8
6.5
13
16
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.6
6.5
23
72
ZXE00
NOMESCO Finland
One hour or less
2.5
6.4
69
396
TKC22
NOMESCO Finland
Catheterisation instruction
28.1
6.3
8
*
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
6.3
6
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
+∞
6.3
6
*
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
9.3
6.2
12
14
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
6.1
60
328
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
6.0
24
81
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
19
25.28
47.37
1.2
1.2
—
—
—
0
0
69
145
8.52
35.58
7.0
2.2
1.14
0.90
e6/l
0.26
45
78
63
132
7.94
32.17
7.5
2.4
5.08
3.97
e6/l
0.23
38
65
83
258
6.56
27.50
10.1
2.4
0.19
0.34
e6/l
0.57
71
183
93
325
6.71
26.90
10.0
2.7
—
—
—
0
0
119
554
9.34
24.16
18.1
5.7
24.77
29.63
%
5.71
119
526
22
0
+∞
23.61
1.4
0.0
—
—
—
0
0
125
663
10.40
20.45
20.8
9.4
3.52
4.03
e9/l
2.60
115
592
29
42
8.48
19.94
1.6
1.3
—
—
—
0
0
25
32
9.32
18.93
1.0
1.3
8.00
2.44
e6/l
1.53
15
25
21
6
40.84
17.24
1.0
1.0
—
—
—
0
0
20
13
17.74
13.08
1.0
1.2
—
—
—
0
0
20
14
16.47
12.73
1.0
1.2
—
—
—
0
0
19
13
16.71
12.20
1.0
1.2
—
—
—
0
0
96
538
3.58
11.15
9.8
4.6
0.00
0.00
estimate
—
9
111
96
548
3.47
10.61
6.7
3.2
0.00
0.00
estimate
—
9
118
95
546
3.37
10.24
6.5
3.3
0.00
0.00
estimate
—
9
105
129
1050
4.50
6.53
30.6
13.0
13.99
14.72
%
1.12
129
1041
26
88
3.41
6.53
1.5
1.8
—
—
—
0
0
10
7
15.26
6.50
1.1
1.0
1753.40
1850.43
miu/ml
—
10
7
138
1238
+∞
5.82
21.8
8.8
26.01
25.34
u/l
0.19
138
1205
25
91
3.13
5.56
1.5
1.8
—
—
—
0
0
23
83
3.13
5.18
2.6
1.7
—
—
—
0
0
15
41
3.98
5.08
1.3
1.8
—
—
—
0
0
25
97
2.93
4.97
3.6
2.1
28.00
28.26
u/l
0.02
20
82
10
15
7.09
4.55
1.3
1.0
—
—
—
0
0
7
7
10.45
4.05
1.6
1.6
—
—
—
0
0
10
21
5.05
3.63
1.3
1.3
—
—
—
0
0
10
21
5.05
3.63
1.3
1.3
—
—
—
0
0
7
9
8.12
3.60
1.0
1.4
—
—
—
0
0
29
143
2.30
3.54
1.7
1.9
—
—
—
0
0
57
373
1.90
3.25
2.1
1.8
92.52
95.08
pmol/l
0.21
32
201
12
35
3.65
3.20
4.1
1.5
101.92
97.97
%
0.23
12
35
12
35
3.65
3.20
7.8
8.1
94.44
95.50
%
0.48
12
35
65
447
1.86
3.16
11.4
6.0
1.21
1.22
mmol/l
0.60
57
377
60
405
1.85
3.07
11.8
5.3
1.21
1.22
mmol/l
0.59
60
375
5
5
10.30
3.00
6.2
1.2
—
—
—
0
0
11
32
3.64
2.97
4.4
1.9
141.18
160.50
%
0.42
11
32
5
6
8.58
2.77
1.0
1.7
—
—
—
0
0
29
160
2.03
2.66
3.1
2.5
64.06
200.07
ng/l
0.52
16
87
5
158
0.29
2.63
1.2
1.5
—
—
—
0
0
124
1085
2.41
2.59
19.4
9.5
97.76
91.42
ml/min/173m2
3.23
110
893
9
26
3.63
2.53
1.0
1.3
—
—
—
0
0
9
26
3.63
2.53
32.2
1.9
24.78
24.68
mmol/l
—
9
26
6
12
5.17
2.43
2.0
2.3
—
—
—
0
0
7
17
4.28
2.39
5.4
1.1
0.00
0.00
g/l
—
7
17
7
17
4.28
2.39
5.4
1.1
0.09
0.00
g/l
—
7
17
7
17
4.28
2.39
5.4
1.1
0.00
0.00
g/l
—
7
17
7
18
4.04
2.28
5.4
1.1
0.59
1.72
g/l
—
7
18
7
18
4.04
2.28
5.4
1.1
38.83
37.89
g/l
—
7
18
7
19
3.82
2.18
5.4
1.1
7.99
10.67
g/l
—
7
19
126
1129
2.33
2.15
21.6
10.5
139.53
139.72
mmol/l
0.32
126
1095
51
359
1.67
2.11
15.8
8.8
1.09
1.11
inr
—
8
118
7
20
3.63
2.08
5.4
1.1
3.11
2.91
g/l
—
7
20
7
22
3.29
1.90
5.4
1.0
3.69
3.61
g/l
—
7
22
7
22
3.29
1.90
5.4
1.0
—
—
—
0
0
7
22
3.29
1.90
5.4
1.0
7.04
7.33
g/l
—
7
22
5
12
4.28
1.84
1.0
1.3
91.20
103.08
%
—
5
12
16
82
2.08
1.78
24.9
5.4
104.38
104.96
mmol/l
0.14
16
82
7
27
2.68
1.53
1.1
1.6
70.29
33.56
nmol/l
—
7
27
14
74
1.99
1.45
6.9
6.0
4.94
5.08
kpa
0.15
14
69
14
74
1.99
1.45
6.9
5.9
13.04
12.78
kpa
0.06
14
69
6
24
2.57
1.32
1.0
1.1
—
—
—
0
0
5
19
2.69
1.22
4.4
4.7
56.80
57.63
%
—
5
19
118
1081
1.63
1.20
6.2
4.8
1.88
1.72
mu/l
0.60
112
1015
11
59
1.94
1.11
26.9
3.0
1.60
2.33
mmol/l
0.36
11
44
11
60
1.91
1.06
26.9
3.0
6.11
5.74
kpa
0.53
11
60
106
1144
0.68
1.02
3.6
3.6
4.84
4.80
mmol/l
0.19
100
1081
35
263
1.44
1.02
2.6
1.7
0.56
0.79
mg/l
1.01
25
196
42
327
1.41
1.01
2.2
2.3
51.26
56.24
u/l
0.80
42
306
106
1139
0.70
0.92
3.5
3.6
1.51
1.51
mmol/l
0.04
99
1075
8
44
1.87
0.87
1.0
1.7
0.25
0.24
g/l
—
8
44
18
253
0.67
0.82
1.2
1.3
1.33
8.12
u/ml
—
6
101
0
27
0.00
0.78
0.0
1.4
—
—
—
0
0
7
44
1.62
0.66
1.3
1.4
—
—
—
0
0
16
113
1.47
0.64
1.6
1.2
93.44
156.40
iu/ml
—
8
45
47
546
0.79
0.62
2.2
2.3
—
—
—
0
0
0
20
0.00
0.61
0.0
1.8
—
—
—
0
0
40
335
1.27
0.58
1.4
1.7
—
—
—
0
0
6
37
1.65
0.56
47.3
2.3
1.40
1.11
%
—
6
37
21
161
1.36
0.56
2.0
1.9
—
—
—
0
0
36
300
1.27
0.54
1.3
1.3
0.64
1.45
u/ml
—
8
88
6
98
0.59
0.54
1.5
1.3
38.03
21.86
iu/l
—
6
82
37
311
1.26
0.52
1.7
1.5
—
—
—
0
0
13
176
0.71
0.50
1.5
1.6
332.00
456.60
pmol/l
2.62
13
156
103
1083
0.81
0.45
3.7
3.7
5.75
5.66
mmol/l
0.24
97
1012
7
51
1.39
0.44
1.6
1.6
—
—
—
0
0
28
232
1.26
0.44
9.2
3.6
12.48
14.49
mg/mmol
0.11
22
139
104
1090
0.81
0.42
3.1
3.2
1.17
1.25
mmol/l
0.82
96
1017
105
997
1.22
0.41
4.4
3.9
—
—
—
0
0
0
16
0.00
0.41
0.0
4.0
—
48.97
—
0
16
32
272
1.23
0.41
9.6
3.6
0.00
0.00
estimate
—
9
110
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
30
255
1.23
0.39
2.1
1.8
—
—
—
0
0
33
284
1.21
0.38
1.5
1.6
1.45
1.34
mmol/l
0.29
28
254
6
45
1.35
0.34
1.2
1.1
—
—
—
0
0
6
87
0.68
0.34
7.7
3.3
—
—
—
0
0
21
248
0.82
0.31
1.5
1.9
—
—
—
0
0
13
160
0.79
0.27
1.5
1.6
—
—
—
0
0
112
1153
0.85
0.26
4.0
3.8
2.91
2.89
mmol/l
0.07
104
1089
9
73
1.25
0.26
2.6
1.6
682.56
330.52
mu/l
—
9
64
9
75
1.21
0.25
3.9
1.6
—
—
—
0
0
5
41
1.23
0.22
1.6
1.4
—
—
—
0
0
15
126
1.21
0.22
2.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
8
68
1.19
0.17
1.6
1.5
—
—
—
0
0
8
70
1.15
0.16
1.8
1.3
—
—
—
0
0
11
92
1.21
0.16
3.5
4.2
16.90
19.91
%
—
5
39
6
73
0.81
0.08
3.0
2.7
34.67
24.85
u/ml
—
6
67
13
118
1.11
0.07
3.5
3.8
1.36
1.70
ug/l
0.51
13
109
43
420
1.03
0.03
9.0
3.2
—
—
—
0
0
12
113
1.07
0.02
7.8
4.8
—
—
—
0
0
33
323
1.03
0.01
3.1
2.9
19.86
19.88
ng/l
0.00
14
164
12
114
1.06
0.01
2.3
2.0
331.92
372.78
nmol/l
0.27
12
104
25
254
0.98
0.00
1.3
1.3
9.60
29.59
iu/ml
—
7
81
27
275
0.98
0.00
1.5
2.0
—
—
—
0
0
7
78
0.89
0.00
1.0
1.4
—
—
—
0
0
5
59
0.84
0.00
1.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
21.10
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.8
—
145.60
—
0
5
0
8
0.00
-0.00
0.0
1.3
—
203.50
—
0
8
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
12.70
—
0
6
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.6
—
248.20
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.34
—
0
5
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
10.66
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
7
73
0.96
-0.00
1.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
9
0.00
-0.00
0.0
1.0
—
158.11
—
0
9
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_RETROBULBNEURINOTH and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have H7_RETROBULBNEURINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: H7_RETROBULBNEURINOTH – Retrobulbar neuritis in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data